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We performed a prospective, observational, cohort study of children newly diagnosed with 
Children’s interstitial lung disease (chILD), with structured follow up at 4, 8, 12 weeks, and 6 
and 12 months. 127 children, median age 0.9 (iqr 0.3, 7.9) years had dyspnoea (68%, 
69/102), tachypnoea (75%, 77/103) and low oxygen saturation (SpO2) median 92% (iqr 88, 
96). Death (N=20, 16%) was commoner in those <6 months of age with SpO2 <94% and 
developmental/surfactant disorders. We report for the first time that chILD survivors 
improved multiple clinical parameters within 8-12 weeks of diagnosis. These data can 





Interstitial lung disease in children (ChILD) encompasses more than 200 entities1, many so 
rare that there is no reported prospective longitudinal disease phenotyping2. Recent 
improvements in adult interstitial lung disease phenotyping has led to better disease 
management. We aimed to utilise the first international collaboration for chILD to 
systematically study new diagnoses for 12 months, to better understand disease 
progression and support the development of clinical outcomes. 
 
METHODS 
This was an observational cohort study of children (<18 years) presenting to participating 
hospitals with a new clinical presentation of chILD, submitted to the chILD-EU Registry 
(www.childeu.net) between December 2013 and March 20163.  Cases were registered 
following brief screening questions and were subject to multidisciplinary peer review to 
standardise diagnostic precision3. Common causes of diffuse lung disease (i.e.  cystic 
fibrosis, respiratory distress syndrome) were excluded. There were 133 incident cases 
during this period. Six were excluded from analysis, leaving 127 reported here (1 time from 
diagnosis too great, 2 airway disease, 1 pleural disease, 2 insufficient data). The enrolment 
date (baseline data) was the study start date. Study variables were collected at baseline, 4, 
8, 12 weeks, and 6 and 12 months (end of the study), and included patient demographics, 
initial diagnoses, family and neonatal history, current history and symptoms, physical 
examination findings, Fan score4, laboratory results and treatments trialed and current (see 
study protocol (https://www.ed.ac.uk/usher/edinburgh-clinical-trials/our-studies/ukcrc-
studies/child-eu) and ChILDEU website (www.childeu.net) for study variables and 
standardisation standard operating procedures)5,6. Biobank materials included (where 
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available) chest radiology (CT), genetic mutation analysis and lung biopsy. Investigation and 
treatment recommendations were standardised7. Ethical and legal approvals and were 
present in all recruiting centres. Fully informed parental consent was obtained prior to study 
inclusion. 
Comparison of continuous variable was by Mann-Whitney test (where only two categories 
i.e. dead/alive) or Kruskal-Wallis test (> two categories i.e. baseline oxygen levels). Missing 
SpO2 values were imputed (see supp methods). Height, weight and BMI were converted to 
Centre for Disease Control z-scores and percentiles8. FEV1 and FVC were converted into 
Global Lung Initiative z-scores and percentiles9.  The trial is registered on clinical trials 
(https://clinicaltrials.gov/ct2/show/NCT02852928) 
 
RESULTS   
Participants were from nine European countries, predominantly Germany, UK and Poland 
(Supp. Table 1). The proportion of participants providing follow up data (or dead) at each 
time point ranged from 76-83% (Supp. Table 2). Median age at baseline was 0.9 (iqr 0.3, 7.9) 
years (Supp. Table 1). Peer review diagnosis, investigations and treatments are provided in 
supplementary information (Supp. Table 3, 4 and 5). At baseline, dyspnoea (68%, 69/102) 
and tachypnoea (75%, 77/103) were frequent, with failure to thrive in 49% (61/125) 
common (Supp. Table 6). Baseline SpO2 in room air ≤94% was recorded in 53% (65/122) at a 
median 92% (iqr 88, 96). Lower baseline SpO2 was most common in younger infants related 
to growth, developmental or surfactant related disorders (Supp. Table 3, Fig 1).  
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There were 20 deaths (16%) over 12 months. Age at death, time from enrolment to death 
and diagnostic group are provided in Supplementary Table 3. Most deaths occurred in 
diffuse developmental disorders (N=6), alveolar surfactant disorders (N=6) and lung growth 
abnormalities (N=3). Age at baseline was significantly associated with survival, with deaths 
in 33% (15/45) of those < 6 months of age compared with 7% (5/74) in those ≥6 months of 
age (log-rank statistic, p=0.0001), Fig 1a. SpO2 at baseline ≥94% was associated with better 
survival (4% died: 2/52), compared with 29% (18/63) of those with SpO2 <94%, (p=0.0006),  
Fig 1b. 
Over 12 months, ventilatory support was utilised in 49 (39%) children, decreasing steeply 
over time with improvement or death (Table 1). Of the 31 children ventilated at baseline, 15 
died (11 invasive, four non-invasive ventilation). Supplemental oxygen was provided to 72% 
(92/127) at any point from baseline to 12 months. The percentage of children in follow up 
recorded as receiving oxygen supplementation declined most markedly from baseline (63%, 
74/117) to 12 week observations (31%, 23/74). For 33 children (26%), SpO2 in air was never 
≥94%, mostly in those who subsequently died or were aged <6 months of age at baseline 
(Table 1). Most improvement in SpO2 in air was observed in the first 8 weeks following 
enrolment (Supp Figs 1a/b and 3).  
There was a progressive reduction over time in Fan scores (Figure 2 and Supp Fig 1c), 
predominantly in the first 12 weeks, but continuing up to 12-months (Supp. Fig 4), with 
deaths more frequent at higher baseline scores (5 (36%, 8/22) and 4 (23%, 9/40)). 
Weight for age at baseline was low and remained so at 12 months (Supp. Table 7).  Most 
improvements in weight and height occurred in the first 4 weeks, with slower gains 
thereafter. Lower weight and height z-score at baseline was significantly associated with 
lower baseline SpO2 and death (Supp. Fig. 5).  
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Median respiratory rate tended to be higher than age related reference values10 at baseline 
but similar to age adjusted reference values by 12 months.  Median heart rate was similar to 
age related reference values across observations10, Supp. Figure 6 (a-d).  
Improvement in FEV1 % predicted and z score continued up to 12 weeks, with little 
subsequent change (Table 1). FVC had a more progressive change over the 12-month 
observation period, again most marked in the first 12 weeks (FVC % predicted median 48% 
to 65%, and to 80% by 12 months).  At baseline 19/25 (76%) spirometry demonstrated a 
restrictive (FEV1/FVC ≥0.8) and 6/25 (24%) an obstructive pattern (ratio <0.8). 
Systemic corticosteroids were provided to 58% (73/125), hydroxychloroquine 28% (35/126), 




We report that many clinical parameters appeared to improve within 8-12 weeks of 
diagnosis and starting treatment in children with chILD. To our knowledge this is the first 
prospective, longitudinal, cohort assessment of chILD. At 12 weeks when compared with 
baseline, provision of oxygen supplementation was observed in 31% fewer children, and 
lung function was 29% greater for FVC and 24% for FEV1. Mean Fan scores were 29% lower 
at 12 weeks. Differences in respiratory rate (and heart rate) across timepoints when related 
to normative data were not observed to have notable differences. We did not however 
provide a formal longitudinal analysis and this together with missing data may have 
impacted the results. We also acknowledge potential bias may have occurred from the 
effect of funding limitations on recruitment in some EU countries and translation of study 
materials. In summary, we have identified key parameters responsive to change in chILD 
 8 
which could be used in trials of treatment and inform prognostic discussions with families. 
Furthermore, we suggest that chILD patients should be seen more frequently in the first 3 
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Survival by Kaplan Meier for (a) age < or ≥ 6 months (b) baseline room air SpO2 < or ≥ 94%. 
 
Figure 2 








This work is a collaboration of European Respiratory Society Clinical Research Collaboration 
for Children's Interstitial Lung Disease (CRC-2015-02), COST Action EnterChILD (CA16125 ) 
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